HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.

Abstract
The introduction of biologic drugs represents the most significant advance in the management of immune-mediated inflammatory diseases for a decade. However, complex proteins are expensive to produce and manufacture. Biosimilar versions of established biologics are becoming available as another version of the reference medicinal product and are expected to provide substantial cost savings. However, because of their complexity, the approval of biosimilars requires strict controls to ensure that all therapeutically relevant characteristics are comparable to the reference medicinal product. This review summarizes the scientific principles and data requirements underpinning regulatory approval of biosimilars and the assumptions that enable extrapolation of data between indications. These important concepts are exemplified by CT-P13 (Remsima(®), Inflectra(®)), the first biosimilar monoclonal antibody approved in Europe.
AuthorsStefan Schreiber, Julian Panés, ByoungOh Kwon, SeungSuh Hong, Laurent Peyrin-Biroulet
JournalExpert review of gastroenterology & hepatology (Expert Rev Gastroenterol Hepatol) Vol. 9 Suppl 1 Pg. 5-15 ( 2015) ISSN: 1747-4132 [Electronic] England
PMID26395530 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • CT-P13
  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
Topics
  • Animals
  • Anti-Inflammatory Agents (adverse effects, pharmacokinetics, therapeutic use)
  • Antibodies, Monoclonal (adverse effects, pharmacokinetics, therapeutic use)
  • Biosimilar Pharmaceuticals (adverse effects, pharmacokinetics, therapeutic use)
  • Drug Approval
  • Gastrointestinal Agents (adverse effects, pharmacokinetics, therapeutic use)
  • Humans
  • Inflammatory Bowel Diseases (diagnosis, drug therapy, immunology)
  • Infliximab (adverse effects, pharmacokinetics, therapeutic use)
  • Therapeutic Equivalency
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: